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Abstract
Introduction The serotonin 5-HT4 receptor agonist prucalopride is approved in the European Union for the treatment of 
chronic constipation. This offered the unique opportunity to include real-world observational data on cardiovascular safety 
in the new drug application for approval of prucalopride in the USA.
Methods This observational population-based cohort study (EUPAS9200) conducted in five data sources (three in the UK, 
one in Sweden, and one in Germany [which was subsequently excluded from the pooled analyses]) aimed to estimate the 
pooled adjusted incidence rate ratio for major adverse cardiovascular events (defined as hospitalization for non-fatal acute 
myocardial infarction or stroke, and in-hospital cardiovascular death) in adult initiators of prucalopride compared with initia-
tors of polyethylene glycol 3350 (PEG) following a common protocol. Standardized incidence rates and incidence rate ratios 
of major adverse cardiovascular events were derived using propensity score stratification. Sensitivity analyses explored the 
impact of exposure definition, outcome categories, interim cancer, and unmeasured confounding.
Results The pooled analyses included 5715 initiators of prucalopride and 29,372 initiators of PEG. Average duration of use 
was 175 days for prucalopride and 82 days for PEG. The pooled standardized incidence rate per 1000 person-years (95% 
confidence interval) of major adverse cardiovascular events was 6.57 (3.90–10.39) for patients initiating prucalopride and 
10.24 (6.97–14.13) for PEG. The pooled adjusted incidence rate ratio for major adverse cardiovascular events was 0.64 (95% 
confidence interval 0.36–1.14). Results remained consistent in various sensitivity analyses.
Conclusions The pooled incidence rate ratio estimate was consistent with no indication of an increased risk above the 
pre-specified safety threshold of 3.00 for major adverse cardiovascular events in patients with chronic constipation using 
prucalopride as compared with PEG.
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Key Points 
Among patients with chronic constipation using pruca-
lopride or polyethylene glycol 3350, the pooled adjusted 
incidence rate ratio of major adverse cardiovascular 
events comparing new use of prucalopride with new use 
of polyethylene glycol 3350 was 0.64 (95% confidence 
interval 0.36–1.14).
The upper limit of the 95% confidence interval for this 
estimate was below the pre-specified safety threshold of 
3.00.
These results were robust to the use of an alternative 
definition of the study endpoint and to bias analyses for 
hypothetical unmeasured confounders, as well as in most 
subgroup analyses.
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1 Introduction
Chronic constipation is a common and often debilitat-
ing medical problem, with an impact on quality of life [1, 
2]. The 5-hydroxytryptamine (serotonin) receptor type 4 
(5-HT4) receptor agonists have the potential to treat disor-
ders of gastrointestinal motility, including delayed gastric 
emptying and colonic dysmotility [3]. The first-generation 
5-HT4 receptor agonists cisapride and tegaserod were with-
drawn from the US market because of serious concerns 
about associated cardiovascular risk, arrythmias thought 
to be associated with QTc prolongation with cisapride, and 
ischemic events of uncertain origin with tegaserod [4].
Prucalopride, a selective 5-HT4 agonist with high affinity 
and selectivity for the 5-HT4 receptors [5], has been licensed 
in the European Union since 2009 for adult women and since 
2015 for adult men for the treatment of chronic constipation 
and is currently approved in 82 countries [6, 7]. No signal 
for an increased risk of adverse cardiovascular events or 
QTc prolongation has been observed for prucalopride dur-
ing non-clinical and clinical cardiovascular investigations or 
as a result of safety monitoring [5]. Nevertheless, given the 
prior serious concern experienced with other 5-HT4 recep-
tor agonists, the US Food and Drug Administration (FDA) 
requested additional information about cardiovascular safety 
outcomes in the new drug application submitted for pruca-
lopride [5].
The primary objective of this study was to estimate, in 
real-world usual care settings, the adjusted incidence rate 
ratio (IRR) and 95% confidence interval (CI) for major 
adverse cardiovascular events (MACE) in initiators of pru-
calopride compared with initiators of polyethylene glycol 
3350 (PEG), two treatments indicated for chronic constipa-
tion. We defined MACE as the composite of hospitalization 
for non-fatal acute myocardial infarction, hospitalization for 
non-fatal stroke, and in-hospital cardiovascular death. For 
the adjusted IRR of MACE among prucalopride initiators 
relative to PEG initiators, the pre-specified safety threshold 
was defined as having an upper bound of the two-sided 95% 
CI of less than 3.00. Secondary objectives were to estimate 
the incidence rates for MACE and its individual compo-
nents in the prucalopride and PEG cohorts, and to estimate 
their adjusted IRRs comparing prucalopride and PEG. This 
article focuses on the results of the primary and secondary 
study outcomes; the study design, general methods, and a 
detailed description of the study cohorts are presented in 
Fortuny et al. [8].
2  Methods
2.1  Study Design
This was an observational population-based cohort study 
of patients initiating prucalopride or PEG from five data 
sources across Germany, Sweden, and the UK (including 
England, Wales, Scotland, and Northern Ireland) following 
a common protocol (EUPAS9200) [9]. Data from Germany 
were excluded from the pooled analyses because the patient 
population was markedly different compared with the other 
countries in terms of comorbidities, likely owing to differ-
ences in prescribing and reimbursement practices for laxa-
tives in Germany as compared with the other countries, as 
well as specifically between prucalopride and PEG within 
Germany [8].
2.2  Setting
The study was originally conducted in five administrative 
healthcare databases across Germany, Sweden, and the UK. 
In the UK, two data sources derived from electronic medi-
cal records from general practices—the Clinical Practice 
Research Datalink (CPRD) and The Health Improvement 
Network (THIN)—and the Information Services Division 
(ISD) of Scotland, an administrative healthcare data source, 
were used. In Sweden, data from the Swedish National 
Registers (SNR) were used, including health data from the 
National Patient Register, the Prescribed Drug Register, the 
Swedish Cancer Register, the Causes of Death Register, and 
information from the Total Population Register. In Germany, 
the German Pharmacoepidemiological Research Database, a 
claims database of four statutory healthcare insurance pro-
viders, was used. Based on the results of an interim analysis 
assessing the characteristics of the study cohorts [8], the 
final pooled analysis presented in this article combined 
the three databases from the UK and the SNR; data from 
Germany were not included because of marked differences 
between prucalopride and PEG initiators, as well as differ-
ences in both cohorts compared with the data sources in the 
UK and Sweden. Patients and practices that overlapped in 
the UK data sources were retained in only one data source 
(see Electronic Supplementary Material 1 of Fortuny et al. 
[8] for more details on each data source).
2.3  Population
Details regarding the inclusion and exclusion criteria are 
presented elsewhere by Fortuny et al. [8]. The prucalopride 
cohort consisted of adult patients who had a dispensing (for 
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claims data sources and the Prescribed Drug Register in 
Sweden) or prescription (as recorded in electronic medical 
record data sources) for prucalopride within the study period 
with at least 12 months of data coverage in the data source 
before this first dispensing or prescription, no evidence in 
the data source of prior use of prucalopride, and no evidence 
of short use of PEG (i.e., < 5 days) within 12 months before 
this first prucalopride prescription/dispensing. The first pre-
scription of prucalopride was the index prescription, which 
determined the index date.
The PEG cohort consisted of patients who had a dispens-
ing or prescription for PEG of at least 5 days within the 
study period, who had at least 12 months of data coverage 
in the data source before this first dispensing or prescription, 
and who had no evidence of prior use of PEG for chronic 
constipation in the data source. The first prescription for 
PEG was the index prescription, prescribed or dispensed 
on the index date. Up to five PEG initiators were selected 
for each prucalopride initiator, matched by age, sex, and 
calendar year of first prescription of prucalopride or PEG. 
(The SNR also matched patients by recent hospitalization 
and specialty of the prescribing physician to increase com-
parability between PEG and prucalopride initiators.) At the 
time of study initiation, PEG was the most commonly pre-
scribed reimbursable medication for chronic constipation in 
Europe. Individuals who switched from PEG to prucalopride 
entered the prucalopride cohort. Individuals who switched 
from prucalopride to PEG were eligible for the PEG cohort.
2.4  Variables
2.4.1  Exposure
Prucalopride or PEG exposure was ascertained from gen-
eral practitioner prescriptions in the CPRD and THIN data 
and by outpatient dispensings in the ISD and SNR data. A 
patient was considered exposed to a study drug if he/she met 
all inclusion and exclusion criteria and had at least 1 day of 
exposure to that study drug alone (i.e., not the whole time at 
risk on overlap exposure time).
A treatment episode was defined as consecutive prescrip-
tions of the index medication separated by gaps of 7 days 
or less, including a 7-day extension period after the drug 
was discontinued. Overlapping time of two prescriptions 
of the same drug was counted only once in the three data 
sources from the UK, while stockpiling was used in Swe-
den and Germany. Identification of drug use was carried 
out using the conventional drug coding schemes at each 
data source. All prucalopride use within the study period 
was accounted for as exposed time (i.e., regardless of the 
duration of the prescription/dispensing). Short episodes of 
PEG (lasting < 12 days) during follow-up were considered 
proxies of indications other than chronic constipation (e.g., 
acute constipation or preparation for a colonoscopy) and 
were ignored, as the comparison cohort was intended to have 
chronic constipation and PEG is assumed to be neutral in 
terms of the risk of MACE (see Fig. 1).
Fig. 1  Inclusion of polyethylene 
glycol 335 (PEG) initiators 
regarding duration of the first 
episode. If a potential new 
initiator of PEG had an episode 
of prior use of PEG lasting less 
than 12 days that included the 
date that marked the beginning 
of the 12-month period before 
the index date (i.e., 12-month 
cut-off date, for short), the 
patient was excluded, as per 
general exclusion criteria, 
because a colonoscopy (or other 
non-chronic constipation indica-
tion of PEG) could have taken 
place at the end of the short 
episode of use, that is, during 
the 12-month period before the 
index date. RX prescription/
dispensing
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2.4.2  Follow‑Up
For the primary analysis, time at risk from current use for 
prucalopride initiators and PEG initiators started on the day 
of index prescription. Time at risk from current use was 
cumulative across all episodes of current use (as described 
above) of the index medication, not including gaps. Accrual 
of time at risk of current use for a study medication was 
terminated if there was a prescription or dispensing for the 
other study medication. Time at risk did not accrue beyond 
7 days after the end of the last prescription/dispensing for 
the index medication, date of death, date of first occurrence 
of the endpoint under evaluation during the time at risk, 
termination of enrolment in the health plan or system, or 
end of the study period.
2.4.3  Outcomes
The main composite cardiovascular endpoint of interest 
for this study was based on the classical MACE endpoint 
ascertained in randomized clinical studies. Definition of this 
endpoint followed FDA recommendations for clinical studies 
summarized in the Standardized Definitions for Endpoint 
Events in Cardiovascular Trials [10] but was adapted to the 
observational setting and the availability of information in 
each data source selected for study implementation, fol-
lowing harmonization criteria to achieve similarity across 
databases. This composite cardiovascular endpoint included 
hospitalization for non-fatal acute myocardial infarction, 
hospitalization for non-fatal stroke, and in-hospital cardio-
vascular death. Individual components of this endpoint were 
also evaluated separately for the secondary objectives. For 
any individual who experienced more than one cardiovas-
cular endpoint (e.g., stroke and myocardial infarction), both 
endpoints would count in the individual component analy-
ses. The individual components of MACE were considered 
secondary endpoints.
Because of the anticipated lack of information on causes 
of out-of-hospital death and the lack of information on out-
patient diagnoses in some of the selected data sources, the 
MACE endpoint for the main analyses included in-hospital 
but not out-of-hospital cardiovascular deaths. This approach 
followed the FDA recommendations for consistent classifi-
cation (i.e., the ascertainment of homogeneous events across 
all selected data sources is preferable to defining endpoints 
based on the maximum available information in each data 
source).
A sensitivity analysis included a composite endpoint 
comprising MACE plus out-of-hospital cardiovascular 
deaths. For the sensitivity analysis that included out-of-hos-
pital cardiovascular deaths as part of the composite MACE 
study endpoint, out-of-hospital cardiovascular death was 
defined as a death occurring out of a hospital setting and 
with evidence of a coronary heart disease, sudden cardiac 
death, or cerebrovascular cause.
In all data sources, potential study endpoints were identi-
fied by electronic algorithms that used operational defini-
tions and lists of diagnostic and procedural codes (using 
International Classification of Diseases codes and/or local 
dictionaries). Potential study endpoints from the UK data 
sources were validated per a common validation plan, which 
included (1) direct confirmation via linkage to hospital 
records (CPRD only); (2) requests for additional clinical 
information through questionnaires (CPRD), free-text com-
ments (THIN), or original hospital case records (ISD); (3) 
patient profile review by study investigators (CPRD/THIN) 
to rule out non-cases; and (4) independent review by two cli-
nicians, blinded to exposure. If there were discrepancies in 
the decision between the two reviewers, the full committee 
(all three clinicians, blinded to exposure) met to review the 
case and come to consensus. Cases were assigned final status 
of definite, probable, possible, or non-cases. Cases included 
in Sweden were identified using modifications of electronic 
algorithms previously validated in the Swedish registers and 
were not further validated. No validation occurred for cases 
identified in Germany.
2.4.4  Covariates
Cardiovascular risk factors, including previous history of 
cardiovascular disease, history of diabetes mellitus, hyper-
tension, dyslipidemia, body mass index (BMI) (or obesity) 
in CPRD, THIN, and SNR, and history of smoking and 
alcohol use in CPRD and THIN, as well as other covariates 
related to gastrointestinal diseases, were identified from the 
available healthcare utilization codes before the index date. 
Table 1 lists the cardiovascular risk factors evaluated.
2.5  Study Size
To estimate the expected statistical power for the final study 
analysis, we used an expected incidence for MACE of 2 
per 1000 person-years. The study size was driven by the 
number of prucalopride initiators and associated duration 
of exposure that was available in the selected data sources 
during the study period. The number of prucalopride initia-
tors was based on an average current-use follow-up time for 
prucalopride initiators of 130 days. Calculations were made 
using the formulas in Episheet [11]. The pre-specified safety 
threshold was defined as having an upper bound of the two-
sided 95% CI for the adjusted IRR of MACE comparing 
prucalopride to PEG initiators of < 3.00. A cohort size of 
10,950 prucalopride initiators was initially targeted to pro-
vide 80% power to reject the hypothesis that the risk ratio 
(RR) is > 3.0 assuming that the true RR is actually 1.0. With 
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these assumptions, a total of 47 patients were expected to 
experience MACE in this study.
2.6  Statistical Analyses
The incidence rate of MACE for prucalopride and PEG ini-
tiators and the adjusted IRRs and incidence rate differences 
(IRDs) of MACE comparing prucalopride to PEG use were 
calculated individually for each data source and after pool-
ing the aggregated results from UK and Sweden. Crude and 
adjusted incidence rates of each outcome of interest were 
calculated for the prucalopride and PEG cohorts by catego-
ries of each covariate of interest, and corresponding crude 
and standardized IRRs and IRDs were estimated. Adjusted 
IRRs and IRDs were calculated using standardization by the 
deciles of the propensity score (PS), derived as explained in 
Fortuny et al. [8]. Pooled analyses of aggregate data were 
conducted by the coordinating center (RTI Health Solu-
tions) and involved standardization of the source-specific 
PS deciles and data source as stratification variables.
2.6.1  Crude Estimates
Person-time at risk, number of events, and crude inci-
dence rates with the corresponding lower bound and upper 
bounds of the exact 95% CI were computed using methods 
described in Dobson et al. [12] for each endpoint overall 
and stratified individually by each covariate of interest for 
each cohort within each data source. Crude IRRs were 
estimated with corresponding exact lower bound and upper 
bound of the 95% CIs calculated using a Poisson distribu-
tion and test-based methods defined in Sahai and Khurshid 
[13]. The crude IRDs with approximate 95% CIs [14] were 
estimated.
2.6.2  Standardized Estimates
Within each data source, the incidence rate, IRR, and their 
95% CIs were standardized by age, sex, and risk factors. 
Within each data source, PSs were developed using logis-
tic regression with prucalopride vs. PEG as the outcome 
and included variables shown to be potential confounders 
for the relationship of the study drugs with MACE, includ-
ing cardiovascular risk factors [8]. Within each data source, 
incidence rates, IRRs, and IRDs were standardized against 
person-years in the prucalopride cohort and stratified by data 
source and PS decile.
The standardized incidence rate (SIR) and exact 95% CIs 
were calculated based on exact methods presented in Dobson 
et al. [12]. The standardized IRRs (SIRRs) with the 95% CIs 
were calculated using a normal approximation as described 
in Rothman et al. [14]. The standardized IRD with 95% CI 
was calculated as shown in Rothman et al. [14].
2.6.3  Pooled Analyses of Aggregate Data
For the pooled results of aggregate data from each included 
data source, the incidence rate, IRR, and IRD were stand-
ardized to the distribution of person-years among each data 
source-specific PS decile in the prucalopride group. For 
each of the endpoints of interest, the results were generated 
and combined across data sources. Specifically, number of 
patients, patients with study endpoints, and person-years 
were added across data sources. Incidence rates and 95% CIs 
standardized for data source and PS decile within each of 
the cohorts were calculated. Incidence rate ratios and IRDs 
per 1000 person-years and their 95% CIs for the prucalo-
pride cohort compared with the PEG cohort, standardized 
for data source and PS decile, were calculated as in Rothman 
et al. [14]. The data source was retained as a stratification 
variable, and the effect within each PS category within each 
database was estimated.
2.6.4  Missing Values
The frequency of missing information was shown in the 
descriptive analyses. When presenting results stratified on a 
single variable, subjects missing information for that vari-
able were reported in a separate category.
Table 1  Cardiovascular risk factors evaluated
a Not included in dichotomous “at least one cardiovascular risk factor” 
variable
b Not available in all data sources, where measured no differences 
observed between prucalopride and polyethylene glycol 3350 patients
Cardiovascular risk factors evaluated
 Inpatient diagnosis or history of ischemic heart disease
 Inpatient diagnosis or history of cerebrovascular disease
 Inpatient diagnosis or history of peripheral vascular disease
 Inpatient diagnosis or history of heart failure
 Coronary or cerebrovascular revascularization
 History of thrombolytic or anticoagulant  usea
 Hyperlipidemia history or treatment
 Hypertension history or treatment




 History of cancer or  treatmenta (excluding non-melanoma)
 Chronic kidney  injurya
 Aged more than 55 years
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2.6.5  Sensitivity Analyses
Sensitivity analyses explored the impact of exposure defi-
nition (including the impacts of extending risk to 30 days, 
evaluating the first episode of use only, including past use, 
and removing periods of time hospitalized), the impact of 
outcome categories (including considering probable cases 
and adding out-of-hospital coronary heart disease and cer-
ebrovascular death to the MACE endpoint), the impact of 
cancer, and the potential for channeling bias. The impact of 
unmeasured confounding was assessed by the bias analy-
sis proposed by Lash et al. [15]; this analysis required an 
a priori specification of the prevalence of the unmeasured 
confounder in the prucalopride and PEG initiators, respec-
tively, and of the effect of the unmeasured confounder on 
the outcome. Finally, post hoc subgroup analyses by sex, 
age, sex by age, and history of cardiovascular disease were 
conducted for the primary pooled analysis.
2.7  Research Ethics
All relevant authorities reviewed and approved the study 
on ethical grounds in the UK (Independent Scientific Advi-
sory Committee for CPRD, Scientific Review Committee 
for THIN, and East of Scotland Research Ethics Services/
Public Benefit and Privacy Panel for Health and Social Care 
for ISD), Germany (all involved health insurance providers, 
as well as the German Federal [Social] Insurance Office and 
the Senator for Science, Health, and Consumer Protection 
in Bremen), and Sweden (Regional Ethical Review Board, 
Stockholm).
3  Results
3.1  Study Population
The pooled analyses of aggregate data included 5715 
patients treated with prucalopride and 29,372 patients 
treated with PEG, including 866 prucalopride patients and 
4254 matched PEG patients (1:5 ratio) from the CPRD, 
501 prucalopride patients and 2543 PEG patients from 
THIN, 1154 prucalopride patients and 5806 PEG patients 
from the ISD, and 3194 prucalopride patients and 16,769 
PEG patients from the SNR. The average durations of 
cumulative prucalopride use and cumulative PEG use after 
the index date were approximately 175 days and 82 days, 
respectively.
In the final pooled trimmed data, the vast majority of 
participants were women (93%), and the proportion of 
patients aged 55 years was 43% for prucalopride and 42% for 
PEG (Table 2). In general, prucalopride and PEG patients 
had similar baseline comorbidities, although prucalopride 
patients had more baseline gastrointestinal comorbidities 
(Table 3). However, after adjusting for the shorter duration 
of use in PEG patients compared with prucalopride patients 
and based on person-years at risk, PEG patients tended to 
have a higher proportion of comorbidities, including prior 
hospitalization for cardiovascular disease, presence of at 
least one cardiovascular risk factor, and cancer in all data 
sources (data not shown). Additional details regarding base-
line comorbidities can be found in Fortuny et al. [8]. 
3.2  Incidence Rates, Incidence Rate Ratios, 
and Incidence Rate Differences of Major 
Adverse Cardiovascular Events in Prucalopride 
and Polyethylene Glycol 3350 Initiators
In the primary analysis, the pooled PS SIR (95% CI) for 
the UK and SNR data sources of MACE among patients 
initiating prucalopride per 1000 person-years was 6.57 
(3.90–10.39) and among patients initiating PEG was 10.24 
(6.97–14.13) (Table 4). The overall pooled adjusted IRR 
was 0.64 (95% CI 0.36–1.14). The pooled adjusted IRD for 
MACE combining the three UK data sources and the SNR 
was − 3.66 per 1000 person-years (95% CI − 8.27 to 0.95). 
The upper limit of the 95% CI of the pooled adjusted IRR 
was below the pre-specified safety threshold of 3.00.
3.3  Secondary Endpoints
In the secondary analyses, the pooled adjusted IRRs 
for individual components of MACE were 0.95 (95% 
CI 0.38–2.39) for hospitalization for non-fatal acute 
Table 2  Sex and age distribution of the study participants: all data 
sources, trimmed population
PEG polyethylene glycol 3350
Patients
Prucalopride PEG
N % n %
Female 5296 93 27,363 93
Male 419 7 2009 7
Age (years)
 18–54 3363 57 17,031 58
 > 55 2452 43 12,341 42
 Women aged 18–54 years 3091 54 16,198 55
 Women aged ≥ 55 years 2205 39 11,165 38
 Men aged 18–54 years 172 3 833 3
 Men aged ≥ 55 years 247 4 1176 4
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Table 3  Baseline characteristics of the study participants included in 
the pooled analysis
Prucalopride PEG
N % n %
Trimmed patient sample 5715 100 29,372 100
Any revascularization procedures
 Yes 139 2 723 2
 No 5576 98 28,649 98
Aspirin and other antiplatelets
 Yes 1001 18 4826 16
 No 4714 82 24,546 84
Statins
 Yes 1200 21 5780 20
 No 4515 79 23,592 80
Antihypertensives
 Yes 2646 46 12,336 42
 No 3069 54 17,036 58
Antidiabetic agents
 Yes 482 8 2393 8
 No 5233 92 26,979 92
Anticoagulants
 Yes 606 11 2958 10
 No 5109 89 26,414 90
Hyperlipidemia diagnosis
 Yes 449 8 2116 7
 No 5266 92 27,256 93
Hypertension diagnosis
 Yes 1018 18 5374 18
 No 4697 82 23,998 82
Obesitya
 Yes 262 6 1534 7
 No 4299 94 22,032 93
Obesity treatments: surgical or pharmaceutical intervention
 Yes 203 4 913 3
 No 5512 96 28,459 97
Diabetes mellitus diagnosis
 Yes 430 8 2136 7
 No 5285 92 27,236 93
Chronic renal disease diagnosis
 Yes 124 2 636 2
 No 5591 98 28,736 98
Cancer
 Yes 439 8 2590 9
 No 5276 92 26,782 91
Smoking (CPRD/THIN only)b
 Never smoker 671 49 3278 48
 Former smoker 424 31 2007 30
 Current smoker 262 19 138 21
 Unknown 10 1 74 1
Table 3  (continued)
Prucalopride PEG
N % n %
COPD diagnosis
 Yes 209 4 1133 4
 No 5506 96 28,239 96
Asthma without COPD diagnosis
 Yes 710 12 2806 10
 No 5005 88 26,566 90
Number of outpatient medical visits with constipation diagnoses 
(CPRD/THIN/SNR only)c
 0 2423 53 19,578 83
 ≥ 1 2138 47 3988 17
Number of medical visits with IBS diagnoses (CPRD/THIN/SNR 
only)c
 0 3712 81 21,975 93
 ≥ 1 849 19 1591 7
Number of unique other gastrointestinal-related outpatient diagno-
ses (CPRD/THIN/SNR only)d
 0 2457 54 15,987 68
 1–12 2104 46 7579 32
Prescription or dispensing for opioid  medicationse
 Yes 1730 30 9810 33
 No 3985 70 19,562 67
Chronic opioid  usef
 Yes 1551 27 7708 26
 No 4164 73 21,664 74
Recent  hospitalizationg
 Yes 248 4 1366 5
 No 5467 96 28,006 95
Economic deprivation category (CPRD/THIN/ISD only)
 Q1 (least deprived) 556 22 2432 19
 Q2 480 19 2322 18
 Q3 506 20 2586 21
 Q4 478 19 2639 21
 Q5 (most deprived) 474 19 2480 20
 Unknown 27 1 144 1
Economic deprivation category (SNR only)
 Q1 (least deprived) 795 25 3648 22
 Q2 784 25 4149 25
 Q3 808 25 4104 24
 Q4 (most deprived) 807 25 4868 29
At least one cardiovascular risk  factorh
 Yes 3297 58 16,136 55
 No 2418 42 13,236 45
Constipation inpatient diagnosis (CPRD/ISD/SNR only)
 Yes 1014 19 869 3
 No 4200 81 25,960 97
IBS inpatient diagnosis (CPRD/ISD/SNR only)
 Yes 168 3 236 1
 No 5046 97 26,593 99
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myocardial infarction, 0.54 (95% CI 0.23–1.29) for 
hospitalization for non-fatal stroke, and 0.47 (95% CI 
0.13–1.67) for in-hospital cardiovascular death.
3.4  Sensitivity Analyses
Sensitivity analyses revealed the pooled adjusted IRR and 
IRD results to be generally robust to the alternative defini-
tions of exposure and outcome categories, to the impact of 
cancer, and to bias analyses that considered the hypothetical 
impact of unmeasured confounding in different scenarios 
of confounder prevalence and associations with the out-
comes. Specifically, the analyses of first episode of use only, 
extension to 30 days of risk, and past use yielded similar 
pooled adjusted IRRs (0.69 [95% CI 0.34–1.42], 0.65 [95% 
CI 0.38–1.09], and 0.65 [95% CI 0.45–0.92], respectively) 
to that from the main analysis (0.64 [95% CI 0.36–1.14]) 
(Table 5). The analysis including out-of-hospital cardio-
vascular deaths in the MACE definition yielded a pooled 
adjusted IRR (0.43 [95% CI 0.25–0.73]), lower than that of 
the main analysis, whereas the pooled adjusted IRR when 
probable cases were included was higher than in the main 
analysis: 0.75 (95% CI 0.27–2.05).
In the analysis evaluating the potential impact of a hypo-
thetical unmeasured confounding factor on the overall IRR 
for each data source, a range of hypothetical values for 
the prevalence of an unknown confounder among the two 
cohorts and for the IRR of the unknown confounder and 
the outcome of interest was used to assess the hypothetical 
potential impact of an unknown confounder on the over-
all IRR for each individual data source. The bias analyses 
showed that adjustment for hypothetical additional con-
founding factors under various assumptions did not change 
the direction of the associations observed in the main anal-
yses, even in unlikely scenarios of an extremely different 
prevalence of the unmeasured confounder between the two 
exposure groups (e.g., over 70% in one group and nearly 
absent in the other group) and of a strong association with 
the MACE outcome.
Table 4  Standardized incidence rate ratios (SIRRs) and standardized 
incidence rate differences (SIRDs) of major adverse cardiovascular 
events comparing prucalopride and polyethylene glycol 3350 (PEG) 
initiators, overall and by individual data sources (standardized to the 
distribution of person-years among each data source-specific propen-
sity score decile in the prucalopride group)
Incidence, IRR, and IRD standardized against the distribution of person-years in each decile of the prucalopride cohort in each data source
CI confidence interval, CPRD Clinical Practice Research Datalink, IR incidence rate, IRD incidence rate differences, IRR incidence rate ratio, 
ISD Information Services Division, SIR standardized incidence rate, SNR Swedish National Registers, THIN The Health Improvement Network
a Crude and standardized IRs for prucalopride were identical because the prucalopride cohort was used as the reference in each data source
SIR per 1000 person-years, 
prucalopride (95% CI)a
Crude IR per 1000 person-
years, PEG (95% CI)
SIR per 1000 person-
years, PEG (95% CI)
SIRR (95% CI) SIRD (95% CI)
Pooled 6.57 (3.90–10.39) 11.12 (8.72–13.98) 10.24 (6.97–14.13) 0.64 (0.36–1.14) − 3.66 (−8.27 to 0.95)
UK (CPRD/
THIN/ISD)
2.84 (0.77–7.26) 3.12 (1.43–5.93) 4.16 (1.47–8.61) 0.68 (0.19–2.38) − 1.33 (−5.59 to 2.94)
SNR 10.55 (5.77–17.70) 17.38 (13.39–22.20) 16.69 (10.80–23.79) 0.63 (0.33–1.20) − 0.01 (−0.01 to 0.00)
Prucalopride PEG
N % n %
Other gastrointestinal-related inpatient diagnosis (CPRD/ISD/SNR 
only)
 Yes 1564 30 4499 17
 No 3650 70 22,330 83
BMI body mass index, CPRD Clinical Practice Research Datalink, GI 
gastrointestinal, IBS irritable bowel syndrome, ISD Information Ser-
vices Division, MACE major adverse cardiovascular events, na not 
applicable, PEG polyethylene glycol 3350, SNR Swedish National 
Registers, THIN The Health Improvement Network
a Not available for ISD. For CPRD and THIN, defined as whether or 
not a BMI > 30  kg/m2 documented within the prior 3  years and for 
SNR based on recorded diagnosis of obesity prior to cohort entry date
b Identified using the information reported closest in time to the 
cohort entry date within the prior 10 years
c Diagnoses occurring any time before taking the index study medica-
tion
d Total number of unique other GI diagnoses occurring any time 
before the index study medication. Other GI diagnoses considered 
were esophageal conditions, gastroduodenal conditions, appendici-
tis, hernias, intestinal conditions, peritonitis, liver conditions, biliary 
conditions, pancreatic conditions, GI hemorrhage, malabsorption, and 
inflammatory bowel disease
e Occurring in the 6 months before cohort entry
f Chronic opioid use was defined as more than one unique prescription 
or dispensing (i.e., occurring on separate days) for an opioid during 
the 12 months before the index date
g Any hospitalization, regardless of diagnosis, in the 14 days immedi-
ately preceding cohort entry
h History of cardiovascular disease (including all MACE component 
endpoints), hypertension, smoking, hyperlipidemia, diabetes, aged 
more than 55 years, or a BMI greater than 30 kg/m2
Table 3  (continued)
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3.5  Subgroup Analyses
In all subgroup analyses, the 95% CIs for the pooled 
adjusted IRR were wide and included the null value. In 
general, all post hoc subgroup analyses were consistent 
with the overall results, except in the subgroup of men 
older than 55 years of age, where a pooled adjusted IRR 
of 2.57 (95% CI 0.71–9.26) was observed (Fig. 2).
3.6  Results in Germany
Although Germany was not included in the pooled main 
analyses, results for the primary study endpoint are presented 
Table 5  Sensitivity analyses: pooled adjusted incidence rates (IRs) and standardized incidence rate ratios (SIRRs)
Incidence and IR standardized against the person-years in the prucalopride cohort




IR (95% CI) PEG events IR (95% CI) SIRR (95% CI
Overall pooled analysis 18 6.57 (3.90–10.39) 73 10.24 (6.97–14.13) 0.64 (0.36–1.14)
Impact on exposure definition
 First episode of use only 10 7.92 (3.80–14.56) 48 11.39 (7.63–16.05) 0.69 (0.34–1.42)
 30-day risk extension 20 6.31 (3.85–9.75) 97 9.76 (7.11–12.86) 0.65 (0.38–1.09)
 Including past use 39 4.42 (3.15–6.05) 341 6.86 (5.81–7.99) 0.65 (0.45–0.92)
 Impact of outcome categories
 MACE + out-of-hospital cardiovascular deaths 18 6.57 (3.90–10.39) 119 15.39 (11.41–19.94) 0.43 (0.25–0.73)
 UK only pooled 4 2.84 (0.77–7.26) 9 4.16 (1.47–8.61) 0.68 (0.19–2.38)
 Inclusion of probable cases (UK only) 6 4.25 (1.56–9.26) 15 5.69 (2.65–10.17) 0.75 (0.27–2.05)
Impact of cancer
 Non-cancer only 16 6.22 (3.56–10.11) 55 9.76 (6.20–14.12) 0.64 (0.34–1.19)
Fig. 2  Pooled adjusted incidence rate ratio (IRR) [95% confidence 
interval (CI)] by sex, age, sex-age strata, and by history of cardio-
vascular (CV) disease at baseline. The IRR was standardized against 
the person-years in the prucalopride cohort. Calendar Period #1 
corresponds to 2010–2012, and Calendar Period #2 corresponds to 
2013–2016 for the three UK databases and 2013–2014 for the Ger-
man Pharmacoepidemiological Research Database. For the Swedish 
National Registers, Calendar Period #1 corresponds to year 2012 and 
Calendar Period #2 corresponds to 2013–2015. aHospitalization for 
CV disease = history of hospitalization for acute myocardial infarc-
tion, stroke, transient ischemic attack, ischemic heart disease, or 
peripheral vascular disease. bHistory of CV disease = history of acute 
myocardial infarction, stroke, hypertension, smoking, hyperlipidemia, 
diabetes mellitus, aged more than 55  years, or a body mass index 
greater than 30 kg/m2. PEG polyethylene glycol
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for transparency. In the German Pharmacoepidemiologi-
cal Research Database, 30,714 prucalopride and matched 
PEG initiators were identified after trimming (88% female 
patients and 66% of patients aged 55 years and older). In 
general, the proportion of history of comorbid conditions 
at baseline was lower in prucalopride patients than in PEG 
patients. The PS deciles SIR of MACE per 1000 person-
years was 11.05 (95% CI 8.03–14.69) for prucalopride and 
21.53 (95% CI 18.52–24.78) for PEG. The adjusted IRR for 
MACE was 0.51 (95% CI 0.37–0.71), and the adjusted IRD 
for MACE was −10.48 (95% CI − 14.99 to − 5.98).
4  Discussion
This study aimed to investigate whether there was evidence 
of an increased risk of cardiovascular events in patients 
treated with prucalopride compared with patients treated 
with PEG. The estimated IRR was 0.64 (95% CI 0.36–1.14), 
with a 95% CI that included the null value and an upper 
limit below 3.00, the pre-specified safety threshold. In the 
post hoc subgroup analysis for men over the age of 55 years, 
a pooled adjusted IRR of 2.57 (95% CI 0.71–9.26) was 
observed, based on four cases exposed to prucalopride and 
11 cases exposed to PEG. This observation should be inter-
preted with caution given the small size of this subgroup 
analysis (as expected, given prucalopride is mostly used in 
women). In sensitivity analyses conducted to explore the 
impact of alternative definitions of exposure, outcome cat-
egories, and of cancer, the results were consistent with those 
from the main pooled analysis. The main results were also 
robust to potential unmeasured confounders.
4.1  Interpretation
The first-generation 5-HT4 receptor agonists cisapride and 
tegaserod were withdrawn from the US market because of 
concerns about their associations with cardiovascular risks. 
In comparison, prucalopride is a more selective 5-HT4 ago-
nist showing greater differential affinity and selectivity for 
the 5-HT4 receptors, with low affinity for other receptors 
[5]. We did not detect an increase in cardiovascular risk in 
patients treated with prucalopride in this study. Prior non-
clinical studies, clinical trials, and safety extension studies 
have found no evidence of increased cardiovascular risk with 
prucalopride [5].
Some differences in prucalopride usage patterns were 
noted in this study. Although the proportion of patients aged 
55 years and older was similar across the UK data sources 
(34% in the CPRD, 31% in THIN, and 21% in ISD), the 
proportion of such patients was higher in Sweden (53%). 
Moreover, the usage differences in Germany precluded pool-
ing with the other data sources. In this context, the incidence 
rates in this study were higher than anticipated, driven pri-
marily by an older population in Sweden. Importantly, the 
FDA accepted evidence from this study in place of a car-
diovascular outcomes trial for the prucalopride new drug 
application in the USA [5].
4.2  Study Limitations
Some limitations of this study must be acknowledged. 
First, determining exposure duration accurately is challeng-
ing when using secondary healthcare data, and exposure 
misclassification in this study was possible. Additionally, 
although the results are subject to confounding (as with 
effect estimates derived from healthcare database studies), 
confounding by the main variables related to cardiovascular 
risk was controlled through matching during specification of 
the PEG cohort and the use of exposure PSs in the analyses. 
The SNR did not have information on BMI or smoking or 
alcohol use, all important risk factors for MACE. However, 
the bias analysis showed that unreasonable scenarios of con-
founder association with exposure and outcome should occur 
to change the direction of the association detected.
No direct measure of patient adherence was available, and 
it was assumed that patients were administered the product 
as prescribed or dispensed. Efforts were made to harmonize 
the definitions of exposure periods and key study variables, 
including endpoints and key covariates, across data sources 
using a common protocol. Still, nuances were allowed for 
endpoint definitions, such as the definition of sudden cardiac 
death in the SNR, to adapt the core definitions to the local 
coding practices and thus avoid outcome misclassification. 
Similarly, minor adaptations were also allowed for some 
covariates included in the analyses.
The primary objective was aimed at examining the 
risk of cardiovascular events in the overall population of 
patients taking prucalopride compared with PEG and was 
not designed to examine risk in subgroups. Although older 
men had an IRR of 2.57, the confidence interval was wide 
and based on a low number of events. Older men are at a 
higher risk for cardiovascular events than younger men or 
women. When examining patients who had at least one risk 
factor for a cardiovascular event or had been hospitalized, 
there was no indication of an increased risk in patients tak-
ing prucalopride compared with PEG.
Note that arrhythmias and symptomatic palpitations 
were not the subject of the present study, as observational 
studies are not well suited to capture such outcomes. How-
ever, previous studies have not shown an effect of pruca-
lopride on QT prolongation [5]. Instead, the present study 
focused on the putative objective adverse cardiovascular 
outcomes of prucalopride exposure, as these outcomes are 
the important potential toxicities of concern. Finally, the 
German data from the German Pharmacoepidemiological 
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Research Database could not be used as originally planned 
because of unadjustable differences in the patient profiles 
between PEG and prucalopride patients and different base-
line characteristics of the population compared with other 
data sources.
Polyethylene glycol 3350 was selected as a comparator 
because of its extensive use in chronic constipation and 
its presumed lack of any cardiovascular effect. The fact 
that we observed a slightly higher incidence of MACE 
events in PEG patients most likely reflects the unexpect-
edly higher baseline cardiovascular risk in the PEG popu-
lation after adjusting for duration of use that could not be 
completely controlled through our analytic methods.
5  Conclusion
In this study of patients with chronic constipation using 
prucalopride or PEG (> 90% women), the pooled adjusted 
IRR of MACE comparing new use of prucalopride with 
new use of PEG was 0.64 (95% CI 0.36–1.14). Of note, 
the upper limit of the 95% CI for this estimate was below 
the pre-specified threshold of 3, which was the threshold 
set by regulatory authorities to define safety in this study. 
These results were robust to the use of an alternative defi-
nition of the study endpoint (i.e., including out-of-hospi-
tal cardiovascular death), as well as to bias analyses for 
hypothetical unmeasured confounders. Results were also 
consistent in post-hoc subgroup analyses, except for the 
small subgroup of men older than 55 years of age where 
additional analyses are warranted.
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